APGE - NASDAQ

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%

HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$5.21B

EPS-4.2200

P/E Ratio-19.95

Earnings Date08/10/2026

No Revenue Data

APGE has not reported any revenue values in the available annual periods.

-255.84M

Net Income

40%

3Y+543.0%

5Y+543.0%

10Y+543.0%

-227.45M

Operating Cash Flow

33%

3Y+1285.0%

5Y+1285.0%

10Y+1285.0%

Apogee Therapeutics, Inc. Profit Bridge

APGE · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (1.42M)

Gross Profit-1.42M

Operating Expenses

Operating Expenses (284.18M)

Operating Income-285.60M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense30.03M

Pretax Income-255.56M

Income Tax (278.00K)

Net Income-255.84M

Net Income

-255.84M

Profitability Analysis

Apogee Therapeutics, Inc. Income Statement

APGE • NASDAQ

Apogee Therapeutics, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022
REVENUE
GROSS PROFIT
Cost of Revenue	(1.4M)	(0.0)	(0.0)	(0.0)
Gross Profit	-1.4M	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(284.2M)	(216.9M)	(93M)	(30.7M)
Selling, General & Administrative	(70.9M)	(49M)	(24.6M)	(2.9M)
Research & Development	(214.7M)	(167.9M)	(68.4M)	(27.8M)
Operating Income	-285.6M	-216.9M	-93M	-30.7M
PRE-TAX INCOME
Interest Expense	(0.0)	(0.0)	(0.0)	(9.2M)
Net Interest Income	30M	34.7M	9M	-9.1M
Total Other Income Expenses Net	30M	34.7M	9M	-9.1M
Income Before Tax	-255.6M	-182.1M	-84M	-39.8M
NET INCOME
Income Tax Expense	(278K)	(18K)	(0.0)	(0.0)
Net Income	-255.8M	-182.1M	-84M	-39.8M

SEC Filings

APGE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 27, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 21, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing

Showing 1 to 10 of 53 filings

Related Guides

Blog Categories

Continue your APGE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.